Nearly 37 million Americans live with some form of kidney disease, and about 700,000 of them have progressed to kidney failure, a condition with no cure, only a treatment that takes over 12 hours of their week for the rest of their lives.

In this episode, we talk with DaVita CEO Javier Rodriguez about what it actually takes to keep hundreds of thousands of patients alive through dialysis, and what it’s like running one of the largest chronic care companies on the planet.

Sarah Russell picked up a phrase at her new job at Anthropic: a "non-regrettable primitive." It's how she describes the kind of infrastructure she thinks Anthropic should be building in healthcare, and it says a lot about how one of the most closely watched companies in health AI is positioning itself. 

In this episode, Steve talks with Sarah Russell, healthcare and life sciences lead at Anthropic. This conversation comes as Anthropic heads toward what's shaping up to be one of the most anticipated IPOs in years.

This week, Halle sits down with Eric Ries, author of Incorruptible, to unpack the rise of shareholder primacy, what it is, and why he believes it's at the root of many of society’s biggest challenges. They discuss the surprising history of corporate governance, the lessons behind Novo Nordisk's century-long success, and what founders can do today to keep their companies aligned with their mission as they grow.

Nearly one billion prescriptions are abandoned at the pharmacy counter every year, often because patients are blindsided by the cost.

This week, co-host Halle Tecco is joined by Wendy Barnes, President and CEO of GoodRx, to discuss the chaos of prescription drug pricing, the murky world of Pharmacy Benefit Managers (PBMs), and how digital tools are changing patient affordability. They break down the layered system of manufacturers, payers, and pharmacies that creates inconsistent pricing, and explore the current push for greater transparency.

Pete McCanna, CEO of Baylor Scott & White Health, believes that health systems are built around the wrong objective… and he has an ambitious goal to change that.

This week, Halle sits down with McCanna to unpack how one of the largest and most successful health systems in the country is shifting from a supply-driven model to one built entirely around the customer. They discuss why legacy systems operate like “walled castles,” what it takes to redesign care around real conditions instead of departments, and how Baylor Scott & White is testing a model that prioritizes access, personalization, and long-term trust over short-term profit.

This week, Halle and Michael sit down for a special in-person listener Q&A to answer a range of founder questions you submitted.

Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care.

In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics.

Physicians now face a world where search bars, chat apps, and large AI models are becoming many people’s first stop for health questions, long before they enter a clinic.

Former Google Chief Health Officer and national health IT leader Dr. Karen DeSalvo joins us to unpack what this shift means for clinicians, regulators, and patients, and why 15% of daily Google searches are questions no one has ever asked before.

Over 3 million clinicians around the world depend on UpToDate to guide patient care, and now the gold standard in clinical decision support is integrating generative AI. But in a world where AI models often hallucinate, how do you build something that doctors can actually trust?

One in four Americans is enrolled in Medicaid, yet the system designed to support them is constantly at risk—underfunded, politically vulnerable, and often overlooked.

Dexcom generates more than $4 billion in annual revenue and has a market cap north of $30 billion, making it one of the biggest digital health companies in the world. And it all started with a better way to measure blood sugar.

Over half of Americans now live with at least one chronic condition, yet our healthcare system still revolves around episodic, reactionary care instead of continuous, coordinated support.

Over 160 million Americans are served by Optum, yet many still don’t fully understand what it actually does—or why it matters.

The Mark Cuban Cost Plus Drug Company